AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS). The VERONA study ...